CD274 and urogenital neoplasm: To comprehensively evaluate the performance of the MLRS for predicting immunotherapeutic efficacy in ccRCC patients, we first conducted a detailed analysis of urogenital cancer patients treated with PD-L1 blockade in the IMvigor210 cohort.